Objective Patients with COVID-19 presented with an elevated prevalence of
antiphospholipid antibodies (aPL) but the relationship with thrombosis is controversial. We …

Background Interest in complications and sequelae following Coronavirus disease 2019
(COVID-19) is increasing. Several articles have reported COVID-19-associated autoimmune …

The clinical significance of antiphospholipid antibodies (aPL) in the context of infections has
attracted attention since their first discovery in patients with syphilis. In fact, the recognition of …

Antiphospholipid antibodies (aPL), assumed to cause antiphospholipid syndrome (APS), are
notorious for their heterogeneity in targeting phospholipids and phospholipid-binding …

The current COVID-19 pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has led to distinct diagnostic and management challenges for …

We report a patient with severe Covid-19-associated coagulopathy and type 2 diabetes
mellitus who tested positive for antiphospholipid antibodies (aPL). Analysis of skin …

Objective To explore whether inactivated coronavirus disease 2019 vaccine influences the
profile of prothrombotic autoantibodies and induces thrombotic events in primary APS …

Background Several viral and bacterial infections, including COVID-19, may lead to both
thrombotic and hemorrhagic complications. Previously, it has been demonstrated an “in …

The high morbidity and mortality of COVID-19 have been associated with the thrombotic
microangiopathy described in the patients in addition to the increased prevalence of …

Objective The clinical relevance of antiphospholipid antibodies (aPLs) in COVID‐19 is
controversial. This study was undertaken to investigate the prevalence and prognostic value …